CStone Out-licenses Ex-China Rights for Two Immunotherapies in $1.3 Billion Agreement

CStone Pharma out-licensed global rights (ex- China) for two immunoncology assets to US-based EQRx in a $1.3 billion agreement. EQRx will own rights to sugemalimab, an anti-PD-L1, and CS1003, an anti-PD-1. CStone will receive $150 million upfront and up to $1.15 billion in milestone payments, plus royalties. EQRx was formed with the goal of bringing novel drugs to global markets at lower prices than the competition. In September, CStone sold China commercialization rights for sugemalimab to Pfizer in a $200 million deal. More details.... Stock Symbol: (HK: 2616)  Share this with colleagues: // //